Taken together, these findings strongly support the recent recommendations that SGLT2 inhibitors should be considered as first-line therapy, alongside metformin, for the management of all people with T2D with or at high risk of developing CKD (15). The gene discussed is SLC5A2; the disease is chronic kidney disease.